A950130 Stock Overview
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Access Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩11,450.00 |
| 52 Week High | ₩14,700.00 |
| 52 Week Low | ₩7,180.00 |
| Beta | 0.26 |
| 1 Month Change | 42.24% |
| 3 Month Change | 42.95% |
| 1 Year Change | 0.88% |
| 3 Year Change | -50.65% |
| 5 Year Change | 144.66% |
| Change since IPO | 10.63% |
Recent News & Updates
Shareholder Returns
| A950130 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -3.9% | -5.2% | -3.5% |
| 1Y | 0.9% | 17.7% | 13.9% |
Return vs Industry: A950130 underperformed the KR Medical Equipment industry which returned 17.7% over the past year.
Return vs Market: A950130 underperformed the KR Market which returned 13.9% over the past year.
Price Volatility
| A950130 volatility | |
|---|---|
| A950130 Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in KR Market | 12.3% |
| 10% least volatile stocks in KR Market | 3.2% |
Stable Share Price: A950130 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: A950130's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 93 | Young-Ho Choi | https://accessbio.net |
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company was founded in 2002 and is headquartered in Somerset, New Jersey.
Access Bio, Inc. Fundamentals Summary
| A950130 fundamental statistics | |
|---|---|
| Market Cap | ₩386.57b |
| Earnings (TTM) | ₩8.26b |
| Revenue (TTM) | ₩398.05b |
46.8x
P/E Ratio1.0x
P/S RatioIs A950130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950130 income statement (TTM) | |
|---|---|
| Revenue | ₩398.05b |
| Cost of Revenue | ₩159.06b |
| Gross Profit | ₩238.99b |
| Other Expenses | ₩230.73b |
| Earnings | ₩8.26b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 244.60 |
| Gross Margin | 60.04% |
| Net Profit Margin | 2.07% |
| Debt/Equity Ratio | 3.9% |
How did A950130 perform over the long term?
See historical performance and comparison